Uncommon thrombotic complications after SARS-CoV-2 vaccination
Authors:
Dalibor Musil
Authors‘ workplace:
Angiologické centrum, I. interní klinika – kardiologická FN a LF Olomouc
Published in:
Vnitř Lék 2021; 67(5): 297-302
Category:
Review Articles
Overview
Shortly after the worldwide initiation of vaccination against SARS-CoV-2, concerns emerged about a possible link between vaccination, severe thrombocytopenia, and the development of atypical venous thrombosis. Concerns were primarily about AstraZeneca (ChAdOx1 nCov-19), later Johnson & Johnson (Ad26.COV2.S), but cases of acute immune thrombocytopenic purpura (ITP) and bleeding without thrombosis and also atypical venous thrombosis after exposure to the messenger RNA-based vaccines produced by Pfizer-BioNTech and Moderna have been reported. Examination of the circumstances of these complications revealed that this is a similar mechanism to heparin-induced thrombocytopenia (HIT), a prothrombotic thrombocytopenic hypercoagulable disorder with venous and arterial thrombosis. HIT is caused by platelet-activating IgG antibodies directed against an antigen that is a macromolecular complex consisting of platelet factor 4 (PF4) and heparin. Naming this new entity vaccine-induced immune thrombotic thrombocytopenia (VITT) was suggested to avoid confusion with HIT. Patients had high levels of antibodies to the immune complex formed by PF 4 and the polyanionic component of the vaccine (double-stranded DNA). In patients with thrombosis at any vascular site after vaccination, accompanied by absolute or relative thrombocytopenia and systemic manifestations, HIT Ig ELISA assay to detect antibodies against PF4 and platelet-activating functional tests may be used for VITT recognition and differentiation from venous thromboembolic disease. Immune globulin impedes antibody-mediated platelet clearance and down-regulate platelet activation by immune complexes, as in HIT. It is prudent to choose from among the nonheparin antithrombotic agents – direct oral F.Xa inhibitors, direct thrombin inhibitors and indirect F.Xa inhibitors for the treatment of thrombosis.
Keywords:
cerebral venous thrombosis – heparin-induced thrombocytopenia (HIT) – vaccine-induced immune thrombotic thrombocytopenia (VITT) – atypical venous thrombosis – portal venous thrombosis – platelet factor 4 – PF4-ELISA HIT assay – PF4 platelet activation functional test
Sources
1. Silvis SM, de Sousa DA. Ferro JM et al. Cerebral venous thrombosis. Nat Rev Neurol 2017; 13: 555–565.
2. Greinacher A, Thiele T, Warkentin TE et al. Thrombotis thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med Published Online First: 9 April 2021. doi: 10.1056/ NEJMoa2104840.
3. Schultz NA, Sǿrvoll IH, Michelsen Ae et al. Thrombosis and thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med Published Online First: 9 April 2021. doi: 10.1056/NEJMoa2104840.
4. Salter BS, Weiner MM, Trinh MA et al. Heparin-induced thrombocytopenia: A comprehensive clinical review. J Am Coll Cardiol 2016; 67: 2519–2532.
5. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. 2007; 83: 575–582.
6. Andreescu AC, Possidente C, Hsieh M, Cushman M. Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia. Pharmacology 2000; 20: 974–980.
7. Kelton JG, Smith JW, Warkentin TE et al. Immunoglobin G from patients with heparin- -induced thrombocytopenia binds to complex of a heparin of heparin and platelet factor 4. Blood 1994; 83: 3232–3239.
8. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 9–16.
9. Hwang SR, Wang Y, Weil EL et al. Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets 2020: 1–5. doi: 10.1080/09537104.2020.1828574. Online ahead of print.
10. Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014; 123: 3651–3654.
11. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502–506.
12. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization. April 5, 2021 (https://covid19.who.int/. opens in new tab).
13. Hursting MJ, Pai PJ, McCracken JE et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134: 774–780.
14. Hughes S. AZ covid vaccine: casual link to severe thrombosis established. Medscape, April 12, 2021.
15. Kaunitz AM. Addressing women´s concerns about the J&J vaccine, Medscape, April 16, 2021.
16. Furie KL. Diagnosis and management of cerebral venous sinus thrombosis with vaccine- induced immune thrombotic thrombocytopenia. Stroke 2021, published online April 29.
17. Taquet M et al. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537 913 covid-19 cases. BMJ Yale 2021, https://www.medrxiv.org/ content/10.1101/2021.04.27.21256153v1 doi: https://doi.org/10.1101/2021.04.27.21256153.
18. Cines DB, Bussel JB. SARS-Cov-2 vaccine-induced thrombotis thrombocytopenia. N Engl J Med 2021; 384: 2254–2256.
19. Cooke MS et al. Immunogenicity of DNA damaged by reactive oxygen species – implications for anti-DNA antibodies in lupus. Free Radic Biol Med 2019; 22: 151–159.
20. McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J Autoimmun. 2021; 121: 102662. doi: 10.1016/j.jaut.2021.102662. Epub 2021 May 19.
21. Greinacher A, Warkentin TE. Recognition, treatment and prevention of heparin-induced thrombocytopenia: review and update. Throm Res 2006; 118: 165–176.
22. Eke S. Heparin-induced thrombocytopenia workup. Medscape, updated: Dec 12, 2019.
23. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611–1617.
24. Irani M, Siegel E, Jella A et al. Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia. Transfusion 2019; 59: 931–934.
25. Mohanty E, Nazir S, Sheppard J-AI et al. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. J Thromb Haemost 2019; 17: 841–844.
26. Dulíček P, Ivanová E, Košťál M et al. Heparin-induced thrombocytopenia treated with fondaparinux: single center experience. Int Angiol 2020; 39: 76–81.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 5
Most read in this issue
- Osteoporosis in premenopausal women
- Osteoporosis in men: underappreciated and undertreated
- Osteoporosis in diabetes mellitus patients
- Uncommon thrombotic complications after SARS-CoV-2 vaccination